Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New pill takes aim at Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
New pill aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis early-stage study tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer and tumors with a specific gene change (CCNE1). The main goals are to find a safe dose and see how well the drug works. About 361 participants will…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:48 UTC